GlycoMimetics Management

Management criteria checks 2/4

GlycoMimetics' CEO is Harout Semerjian, appointed in Aug 2021, has a tenure of 2.75 years. total yearly compensation is $2.39M, comprised of 26.7% salary and 73.3% bonuses, including company stock and options. directly owns 0.039% of the company’s shares, worth €39.94K. The average tenure of the management team and the board of directors is 2.8 years and 7.7 years respectively.

Key information

Harout Semerjian

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage	26.7%
CEO tenure	2.8yrs
CEO ownership	0.04%
Management average tenure	2.8yrs
Board average tenure	7.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Harout Semerjian's remuneration changed compared to GlycoMimetics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$2m	US$638k	-US$37m
Sep 30 2023	n/a	n/a	-US$38m
Jun 30 2023	n/a	n/a	-US$37m
Mar 31 2023	n/a	n/a	-US$42m
Dec 31 2022	US$1m	US$614k	-US$47m
Sep 30 2022	n/a	n/a	-US$54m
Jun 30 2022	n/a	n/a	-US$63m
Mar 31 2022	n/a	n/a	-US$64m
Dec 31 2021	US$3m	US$244k	-US$63m

Compensation vs Market: Harout's total compensation ($USD2.39M) is above average for companies of similar size in the German market ($USD402.64K).

Compensation vs Earnings: Harout's compensation has increased whilst the company is unprofitable.

CEO

Harout Semerjian (53 yo)

2.8yrs

Tenure

US$2,389,418

Compensation

Mr. Harout Semerjian serves as Chief Executive Officer, President & Director of GlycoMimetics, Inc., since August 6, 2021. He served as President and Chief Executive Officer of Immunomedics Inc. since Apri...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Harout Semerjian	CEO, President & Director	2.8yrs	US$2.39m	0.039% $ 39.9k
Rachel King	Co-Founder & Director	21.3yrs	US$96.00k	0.99% $ 1.0m
Brian Hahn	Senior VP & CFO	12.3yrs	US$1.30m	0.056% $ 57.3k
Edwin Rock	Senior VP & Chief Medical Officer	1.7yrs	US$1.15m	0.58% $ 599.8k
Stephanie Irish	Vice President of Accounting	5.3yrs	no data	no data
Christian Dinneen-Long	General Counsel & Company Secretary	5.1yrs	no data	no data
Bruce Johnson	Senior VP & Chief Commercial Officer	2.3yrs	no data	0.22% $ 222.1k
Chinmaya Rath	Senior VP & Chief Business Officer	1.3yrs	no data	0.25% $ 257.5k
Shantha Tyavanagimatt	Senior Vice President of Technical Operations	less than a year	no data	no data

2.8yrs

Average Tenure

53yo

Average Age

Experienced Management: GKO's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Harout Semerjian	CEO, President & Director	2.8yrs	US$2.39m	0.039% $ 39.9k
Rachel King	Co-Founder & Director	21.3yrs	US$96.00k	0.99% $ 1.0m
Daniel Junius	Independent Director	8.2yrs	US$118.50k	0.15% $ 157.3k
Timothy Pearson	Independent Chairman of the Board	10.2yrs	US$138.00k	0.038% $ 39.4k
Scott Koenig	Independent Director	7.2yrs	US$100.50k	0.057% $ 58.7k
Scott Jackson	Independent Director	5.5yrs	US$111.00k	0.0081% $ 8.4k
Patricia S. Andrews	Independent Director	6.9yrs	US$105.00k	0.091% $ 93.6k
Mark A. Goldberg	Independent Director	9.8yrs	US$111.00k	0.056% $ 58.0k

7.7yrs

Average Tenure

64yo

Average Age

Experienced Board: GKO's board of directors are considered experienced (7.7 years average tenure).

GlycoMimetics Management

Management criteria checks 2/4

Key information

Recent management updates

GlycoMimetics, Inc., Annual General Meeting, May 01, 2024

Senior VP & Chief Medical Officer recently bought €85k worth of stock

Chief Medical Officer recently bought €234k worth of stock

Insufficient new directors

GlycoMimetics, Inc. Appoints Edwin Rock as Chief Medical Officer

Insufficient new directors

Recent updates

GlycoMimetics, Inc. to Report Q1, 2024 Results on May 09, 2024

GlycoMimetics, Inc., Annual General Meeting, May 01, 2024

New minor risk - Profitability

GlycoMimetics, Inc. to Report Q4, 2023 Results on Mar 27, 2024

GlycoMimetics, Inc. to Report Q3, 2023 Results on Nov 03, 2023

New minor risk - Share price stability

Senior VP & Chief Medical Officer recently bought €85k worth of stock

GlycoMimetics, Inc. Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687

New minor risk - Market cap size

GlycoMimetics, Inc. Announces U.S. Food and Drug Administration Clears Addition of Time-Based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia

No longer forecast to breakeven

Full year 2022 earnings released: US$0.89 loss per share (vs US$1.23 loss in FY 2021)

GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee

Forecast to breakeven in 2025

Chief Medical Officer recently bought €234k worth of stock

GlycoMimetics, Inc. Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting

Insufficient new directors

Third quarter 2022 earnings released: EPS: US$0 (vs US$0.34 loss in 3Q 2021)

GlycoMimetics, Inc. Appoints Edwin Rock as Chief Medical Officer

Second quarter 2022 earnings released: US$0.25 loss per share (vs US$0.28 loss in 2Q 2021)

GlycoMimetics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

GlycoMimetics Receives a Notice from Nasdaq Regarding Minimum Bid Price Requirement

First quarter 2022 earnings released: US$0.28 loss per share (vs US$0.28 loss in 1Q 2021)

Insufficient new directors

GlycoMimetics, Inc. to Report Q1, 2022 Results on Apr 28, 2022

GlycoMimetics, Inc., Annual General Meeting, May 18, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

GlycoMimetics, Inc. to Report Q4, 2021 Results on Mar 03, 2022

GlycoMimetics, Inc. Appoints Bruce Johnson as Senior Vice President and Chief Commercial Officer

Insufficient new directors

Insufficient new directors

Independent Director recently bought €72k worth of stock

GlycoMimetics, Inc. Announces Efficacy and Safety Data from Phase 1/2 Clinical Study of Uproleselan Published in BLOOD

Trial Launches to Evaluate GlycoMimetics’ Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients

GlycoMimetics, Inc. Announces Initiation of Clinical Trial Evaluating Uproleselan in Combination with Venetoclax and Azacitidine

GlycoMimetics, Inc.(NasdaqGM:GLYC) dropped from Russell 3000E Value Index

GlycoMimetics, Inc. Announces Investigator-Sponsored Phase 2 Clinical Trial Evaluating Uproleselan for Prevention of Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell Transplantation

First quarter 2021 earnings released: US$0.28 loss per share (vs US$0.18 loss in 1Q 2020)

Senior VP of Clinical Development & Chief Medical Officer has left the company

Apollomics, Inc Doses First Patient in Phase 1 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML

Revenue beats expectations

New 90-day low: €2.82

GlycoMimetics, Inc. Announces Resignation of Helen Thackray as Senior Vice President and Chief Medical Officer

New 90-day high: €3.42

GlycoMimetics Program Data to be Highlighted Via Three Oral Presentations and Two Posters at 62nd American Society of Hematology Annual Meeting and Exposition

GlycoMimetics, Inc. to Report Q3, 2020 Results on Nov 06, 2020

New 90-day low: €2.50

GlycoMimetics, Inc. Presents New Pediatric and Secondary Endpoint Data from Rivipansel Phase 3 Reset Trial at the Annual Scientific Conference on Sickle Cell and Thalassemia Meeting

FDA Grants GlycoMimetics Rare Pediatric Disease Designation for Rivipansel for Treatment of Sickle Cell Disease

New 90-day low: €2.64

GlycoMimetics, Inc.(NasdaqGM:GLYC) dropped from Russell 2500 Growth Index

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age